Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
Adult-onset Still’s disease
Anakinra
Canakinumab
Interleukin-1
Rilonacept
Still’s disease
Systemic juvenile idiopathic arthritis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
11 12 2019
11 12 2019
Historique:
received:
16
05
2019
accepted:
03
10
2019
entrez:
13
12
2019
pubmed:
13
12
2019
medline:
10
9
2020
Statut:
epublish
Résumé
Adult-onset Still's disease (AOSD) is a rare inflammatory condition characterized by fever, rash, and arthritis. Because of its rarity, clinical trials are inherently small and often uncontrolled. Our objective was to develop recommendations for the use of interleukin (IL)-1 inhibitors in the management of patients with AOSD, based on the best evidence and expert opinion. A panel of 10 experts (9 rheumatologists and 1 pediatrician) was established. The first step was dedicated to a comprehensive literature review and development of statements. Two separate literature searches were performed on the MEDLINE (Pubmed), EMBASE, and BIOSIS databases through April 2018 to identify (1) differences and similarities between AOSD and pediatric Still's disease (systemic juvenile idiopathic arthritis [SJIA]) and (2) the efficacy and safety of IL-1 inhibitors in AOSD treatment. In the second step, the statements were submitted in a Delphi process to a panel of 67 rheumatologists. Consensus threshold was set at 66%: positive, > 66% of voters selected scores 3 to 5; negative, > 66% of voters selected scores 1 or 2. In the third step, the voting results were analyzed, and the statements were finalized. Eleven statements were developed. Forty-six of 67 rheumatologists (72%) participated in the Delphi process. A positive consensus was reached after the first round of voting and was full (> 95%) on the majority of statements. A large consensus was achieved in considering AOSD and SJIA as the same disease. The use of anti-IL-1 therapies in refractory patients was considered quite safe and effective both as the first and as a subsequent line of biologic treatment, especially in systemic patients. Because of the lack of head-to-head comparisons, a different profile of efficacy among IL-1 inhibitors could not be established. There was a large consensus that failure of the first IL-1 inhibitor does not preclude response to another one. The lack of studies comparing early versus late treatment did not allow to draw conclusions; however, data from SJIA suggest a better response in early treatment. The Delphi method was used to develop recommendations that we hope will help clinicians in the management of patients with AOSD refractory to conventional therapies.
Sections du résumé
BACKGROUND
Adult-onset Still's disease (AOSD) is a rare inflammatory condition characterized by fever, rash, and arthritis. Because of its rarity, clinical trials are inherently small and often uncontrolled. Our objective was to develop recommendations for the use of interleukin (IL)-1 inhibitors in the management of patients with AOSD, based on the best evidence and expert opinion.
METHODS
A panel of 10 experts (9 rheumatologists and 1 pediatrician) was established. The first step was dedicated to a comprehensive literature review and development of statements. Two separate literature searches were performed on the MEDLINE (Pubmed), EMBASE, and BIOSIS databases through April 2018 to identify (1) differences and similarities between AOSD and pediatric Still's disease (systemic juvenile idiopathic arthritis [SJIA]) and (2) the efficacy and safety of IL-1 inhibitors in AOSD treatment. In the second step, the statements were submitted in a Delphi process to a panel of 67 rheumatologists. Consensus threshold was set at 66%: positive, > 66% of voters selected scores 3 to 5; negative, > 66% of voters selected scores 1 or 2. In the third step, the voting results were analyzed, and the statements were finalized.
RESULTS
Eleven statements were developed. Forty-six of 67 rheumatologists (72%) participated in the Delphi process. A positive consensus was reached after the first round of voting and was full (> 95%) on the majority of statements. A large consensus was achieved in considering AOSD and SJIA as the same disease. The use of anti-IL-1 therapies in refractory patients was considered quite safe and effective both as the first and as a subsequent line of biologic treatment, especially in systemic patients. Because of the lack of head-to-head comparisons, a different profile of efficacy among IL-1 inhibitors could not be established. There was a large consensus that failure of the first IL-1 inhibitor does not preclude response to another one. The lack of studies comparing early versus late treatment did not allow to draw conclusions; however, data from SJIA suggest a better response in early treatment.
CONCLUSIONS
The Delphi method was used to develop recommendations that we hope will help clinicians in the management of patients with AOSD refractory to conventional therapies.
Identifiants
pubmed: 31829244
doi: 10.1186/s13075-019-2021-9
pii: 10.1186/s13075-019-2021-9
pmc: PMC6907145
doi:
Substances chimiques
Antirheumatic Agents
0
Interleukin-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
275Commentaires et corrections
Type : ErratumIn
Références
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
Ulster Med J. 2015 May;84(2):130-2
pubmed: 26376493
Medicine (Baltimore). 2014 Mar;93(2):91-9
pubmed: 24646465
ACG Case Rep J. 2015 Apr 10;2(3):173-4
pubmed: 26157954
J Rheumatol. 2004 Nov;31(11):2189-98
pubmed: 15517632
Clin Rheumatol. 2007 Aug;26(8):1359-61
pubmed: 16871352
J Rheumatol. 2017 Jul;44(7):996-1003
pubmed: 28412707
J Rheumatol. 2005 Dec;32(12):2429-31
pubmed: 16331776
J Adv Nurs. 2003 Feb;41(4):376-82
pubmed: 12581103
J Clin Rheumatol. 2003 Oct;9(5):330-2
pubmed: 17041487
Scott Med J. 2018 May;63(2):63-66
pubmed: 29506437
Arthritis Care Res (Hoboken). 2013 May;65(5):822-6
pubmed: 23225779
Clin Exp Rheumatol. 2013 Jan-Feb;31(1):47-52
pubmed: 23010097
Mod Rheumatol. 2010 Apr;20(2):200-4
pubmed: 20037747
Clin Exp Rheumatol. 2011 Nov-Dec;29(6):1021-3
pubmed: 22153586
J Cutan Pathol. 2010 Sep;37(9):932-7
pubmed: 20546088
J Rheumatol. 2019 Feb;46(2):190-197
pubmed: 30275259
Acad Med. 2017 Oct;92(10):1491-1498
pubmed: 28678098
Ann Rheum Dis. 2009 Jan;68(1):153-4
pubmed: 19088261
Case Rep Rheumatol. 2016;2016:3717392
pubmed: 27818826
Case Rep Rheumatol. 2016;2016:6502373
pubmed: 27042373
Arthritis Res Ther. 2011 Jun 17;13(3):R91
pubmed: 21682863
Ryumachi. 1991 Oct;31(5):511-8
pubmed: 1767345
J Eur Acad Dermatol Venereol. 2009 Jan;23(1):104-6
pubmed: 18429988
J Clin Rheumatol. 2009 Jun;15(4):161-4
pubmed: 19363453
Semin Arthritis Rheum. 2007 Dec;37(3):189-97
pubmed: 17583775
Rheumatology (Oxford). 2008 Apr;47(4):555-6
pubmed: 18321945
Rheumatology (Oxford). 2018 Apr 12;:null
pubmed: 29660063
Case Rep Med. 2012;2012:349521
pubmed: 23251171
Arthritis Rheum. 2008 May;58(5):1505-15
pubmed: 18438814
Auto Immun Highlights. 2015 Dec;6(3):39-46
pubmed: 26423534
Int J Rheum Dis. 2010 Aug;13(3):e36-41
pubmed: 20704609
Clin Rheumatol. 1998;17(3):258-60
pubmed: 9694067
J Rheumatol. 2012 Oct;39(10):2008-11
pubmed: 22859346
Ann Rheum Dis. 1971 Mar;30(2):121-33
pubmed: 5315135
Clin Exp Rheumatol. 2011 Mar-Apr;29(2):331-6
pubmed: 21385548
Ann Rheum Dis. 2007 Jun;66(6):842-3
pubmed: 17513574
Rheumatology (Oxford). 2017 Dec 1;56(12):2102-2108
pubmed: 28968868
Rev Med Chil. 1992 Jun;120(6):638-43
pubmed: 1341793
Rheumatology (Oxford). 2012 Sep;51(9):1730-2
pubmed: 22513144
Clin Rheumatol. 2000;19(2):127-30
pubmed: 10791624
Clin Rheumatol. 2016 Jul;35(7):1683-9
pubmed: 27207567
Front Pharmacol. 2017 Jun 13;8:369
pubmed: 28659802
Arthritis Rheum. 2005 Jun;52(6):1794-803
pubmed: 15934079
Pulm Circ. 2016 Mar;6(1):136-42
pubmed: 27162622
J Clin Pharmacol. 2016 Dec;56(12):1516-1527
pubmed: 27119439
J Rheumatol. 2014 Dec;41(12):2403-8
pubmed: 25274901
Clin Rheumatol. 2006 Sep;25(5):639-44
pubmed: 16365690
Case Rep Rheumatol. 2016;2016:4835147
pubmed: 26981304
Arthritis Rheum. 2010 Aug;62(8):2530-5
pubmed: 20506370
Joint Bone Spine. 2014 Jul;81(4):376-7
pubmed: 24462130
Arthritis Rheumatol. 2014 Jun;66(6):1405-13
pubmed: 24623686
Clin Nucl Med. 2015 Jun;40(6):492-3
pubmed: 25742228
Autoimmun Rev. 2014 Jul;13(7):708-22
pubmed: 24657513
Clin Rheumatol. 2010 Oct;29(10):1199-200
pubmed: 20428907
Expert Rev Clin Immunol. 2015 Jun;11(6):749-61
pubmed: 25948106
Drug Des Devel Ther. 2014 Nov 25;8:2345-57
pubmed: 25473268
Rheumatol Int. 2011 Mar;31(3):405-7
pubmed: 19834709
BMC Pharmacol Toxicol. 2013 Aug 05;14:40
pubmed: 23915458
Arthritis Care Res (Hoboken). 2014 Apr;66(4):642-6
pubmed: 24124073
Scand J Rheumatol. 2018 Nov;47(6):511-512
pubmed: 29291663
Pediatr Rheumatol Online J. 2015 Nov 20;13:50
pubmed: 26589963
BMJ. 1995 Aug 5;311(7001):376-80
pubmed: 7640549
Transpl Int. 2013 Nov;26(11):e105-8
pubmed: 23981123
Clin Rheumatol. 2010 Dec;29(12):1465-7
pubmed: 20734215
Ann Rheum Dis. 2010 Feb;69(2):466-7
pubmed: 20107032
Ryumachi. 1993 Oct;33(5):410-5
pubmed: 8256163
Arthritis Res Ther. 2019 Feb 13;21(1):54
pubmed: 30760322
Semin Arthritis Rheum. 2012 Oct;42(2):201-5
pubmed: 22512815
Clin Exp Rheumatol. 2007 Sep-Oct;25(5):758-9
pubmed: 18078628
Ann Intern Med. 2018 Mar 20;168(6):455-456
pubmed: 29230477
Clin Rheumatol. 2008 May;27(5):659-61
pubmed: 18095015
N Engl J Med. 2012 Dec 20;367(25):2396-406
pubmed: 23252526
PLoS One. 2011;6(6):e20476
pubmed: 21694759
J Rheumatol. 1988 Jun;15(6):981-3
pubmed: 3418650
Ann Rheum Dis. 2005 Apr;64(4):647-8
pubmed: 15374853
Mod Rheumatol. 2014 Nov;24(6):1030-1
pubmed: 24313885
Arthritis Rheum. 2009 Nov 15;61(11):1609-13
pubmed: 19877102
Clin Exp Rheumatol. 2008 Sep-Oct;26(5):933-7
pubmed: 19032833
Int J Cardiol. 2015;189:220-2
pubmed: 25897909
Clin Exp Rheumatol. 2012 Sep-Oct;30(5):807
pubmed: 22992345
Joint Bone Spine. 2013 Dec;80(6):653-5
pubmed: 23751410
Arthritis Rheum. 1985 Feb;28(2):146-50
pubmed: 3970730
Front Pharmacol. 2018 Sep 21;9:1074
pubmed: 30298010
Semin Arthritis Rheum. 2016 Jun;45(6):711-6
pubmed: 26672682
Pediatr Rheumatol Online J. 2012 Nov 23;10(1):40
pubmed: 23176399
Clin Exp Rheumatol. 2010 Mar-Apr;28(2):265-7
pubmed: 20483052
J Rheumatol. 2013 Sep;40(9):1632-3
pubmed: 23997005
J Adv Nurs. 2000 Oct;32(4):1008-15
pubmed: 11095242
Ann Rheum Dis. 2012 Dec;71(12):2056-7
pubmed: 22679302
Joint Bone Spine. 2011 Jan;78(1):100-1
pubmed: 21036649
J Rheumatol. 2013 Oct;40(10):1775-7
pubmed: 24085761
Orphanet J Rare Dis. 2015 Feb 15;10:19
pubmed: 25758134
Immunol Res. 2015 Feb;61(1-2):53-62
pubmed: 25388963
Autoimmun Rev. 2014 Nov;13(11):1149-59
pubmed: 25183244
J Rheumatol. 1998 Oct;25(10):1991-4
pubmed: 9779856
J Rheumatol. 1992 Mar;19(3):424-30
pubmed: 1578458
Int J Cardiol. 2014;172(1):e225-7
pubmed: 24461482
Crit Care. 2018 Apr 11;22(1):88
pubmed: 29642928
Scand J Rheumatol. 2015;44(4):309-14
pubmed: 25656459
J Clin Rheumatol. 2018 Apr;24(3):156-158
pubmed: 29239928
Medicine (Baltimore). 2015 Sep;94(39):e1554
pubmed: 26426623
Rev Med Interne. 2013 Mar;34(3):168-70
pubmed: 23182291
Br J Rheumatol. 1995 May;34(5):429-34
pubmed: 7788171
Intern Med J. 2012 Dec;42(12):1358-62
pubmed: 23253002
Ther Clin Risk Manag. 2014 Dec 22;11:33-43
pubmed: 25653531
J Clin Rheumatol. 2008 Dec;14(6):357-8
pubmed: 19033875
Rheumatology (Oxford). 2001 Dec;40(12):1398-404
pubmed: 11752512
Clin Exp Rheumatol. 2018 Jul-Aug;36(4):668-675
pubmed: 29533755
Pediatr Rheumatol Online J. 2018 Jan 25;16(1):9
pubmed: 29370863
Arthritis Rheum. 1977 Mar;20(2 Suppl):271-6
pubmed: 263903
Nihon Rinsho Meneki Gakkai Kaishi. 1995 Feb;18(1):45-52
pubmed: 7553038
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
Medicine (Baltimore). 2017 Jun;96(24):e6656
pubmed: 28614216
Semin Arthritis Rheum. 2014 Apr;43(5):689-91
pubmed: 24176730
Case Rep Med. 2016;2016:2071815
pubmed: 27847518
Semin Arthritis Rheum. 2017 Oct;47(2):295-302
pubmed: 28757235
J Clin Rheumatol. 2014 Mar;20(2):121
pubmed: 24561423
Rheumatol Int. 2012 Jun;32(6):1827-9
pubmed: 21769488
Ann Rheum Dis. 1990 May;49(5):283-5
pubmed: 2344206
Pharmacotherapy. 2016 Jan;36(1):e1-4
pubmed: 26749403
Clin Exp Rheumatol. 2002 May-Jun;20(3):427-30
pubmed: 12102485
Arthritis Rheum. 1985 Apr;28(4):452-4
pubmed: 3986008
J Clin Rheumatol. 2014 Mar;20(2):96-8
pubmed: 24561414
Ann Rheum Dis. 2008 Mar;67(3):302-8
pubmed: 17947302
RMD Open. 2015 Apr 30;1(1):e000036
pubmed: 26509061
Arthritis Rheumatol. 2014 Apr;66(4):1034-43
pubmed: 24757154
Ann Rheum Dis. 2011 Feb;70(2):390-2
pubmed: 20650873